Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05020704
PHASE3

EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction

Sponsor: NHS Greater Glasgow and Clyde

View on ClinicalTrials.gov

Summary

The addition of the SGLT2 inhibitor empagliflozin 10mg once daily to standard-of-care therapy administered early following acute myocardial infarction will result in a greater attenuation of adverse left ventricular remodelling, compared with matched placebo, in patients with left ventricular systolic dysfunction as a result of an acute myocardial infarction.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2022-09-16

Completion Date

2024-06-12

Last Updated

2024-04-02

Healthy Volunteers

No

Interventions

DRUG

Empagliflozin 10 MG

SGLT2inhibitor

DRUG

Placebo

Matched placebo

Locations (3)

Glasgow Royal Infirmary

Glasgow, Strathclyde, United Kingdom

Golden Jubilee National Hospital

Glasgow, United Kingdom

NHS Greater Glasgow and Clyde

Glasgow, United Kingdom